{"product_id":"sgmo-vrio-analysis","title":"Sangamo Therapeutics, Inc. (SGMO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking sustainable competitive advantage for Sangamo Therapeutics, Inc. (SGMO) hinges on a critical assessment: are its core resources truly Valuable, Rare, Inimitable, and Organized? This VRIO analysis distills the answer, providing a sharp summary of the firm's strategic position, as detailed in \u0026amp;O4\u0026amp;. Read on to uncover the definitive verdict on whether Sangamo Therapeutics, Inc. (SGMO) possesses the foundation for long-term market dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSangamo Therapeutics, Inc. (SGMO) - VRIO Analysis: 1. Proprietary Zinc Finger (ZF) Epigenetic Regulator Technology\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at Sangamo Therapeutics, Inc. (SGMO)'s core engine - the Zinc Finger (ZF) technology. This isn't just another gene therapy tool; it's a platform designed for precise, durable control over gene expression, which is a big deal for chronic diseases. Think about ST-503, their candidate for intractable pain from small fiber neuropathy (SFN). The FDA recently granting it Fast Track Designation on December 2, 2025, validates the high unmet need and the potential of this approach to offer a nonopioid alternative.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Precision and Durability in Gene Regulation\u003c\/h3\u003e\n\u003cp\u003eThe value proposition here is turning genes on or off with high accuracy without making permanent cuts to the DNA helix. This epigenetic control is critical when you need long-term, fine-tuned management, not just a one-time genetic fix. For ST-503, the nonclinical data presented in September 2025 showed potency and durability in nonhuman primates, supporting its development for chronic neuropathic pain. That's real value; it means potentially fewer side effects and a longer therapeutic window.\u003c\/p\u003e\n\u003cp\u003eKey Value Drivers:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNon-cutting, precise gene regulation.\u003c\/li\u003e\n\u003cli\u003ePotential for durable, long-term effect.\u003c\/li\u003e\n\u003cli\u003eSupports pipeline assets like ST-503 for chronic pain.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eRarity: A Specialized, Mature Toolset\u003c\/h3\u003e\n\u003cp\u003eWhile CRISPR has taken the spotlight, the ZF toolset is more specialized and, frankly, more mature for certain regulatory tasks. It's less common to see companies deeply invested in validating large libraries of highly specific ZFs compared to the rush toward newer editing systems. This specialization makes the existing, validated library of ZFs a rare asset in the current landscape. It's a different kind of tool, like having a specialized micrometer when everyone else is using a ruler.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: High Barrier Due to Expertise and Validation\u003c\/h3\u003e\n\u003cp\u003eHonestly, imitating this isn't a weekend project. Building and proving a library of ZFs that are both highly selective and safe enough for human use takes years of dedicated, specialized scientific effort. It’s not just about the code; it’s about the deep, institutional knowledge to design, test, and validate the specificity across many targets. This deep expertise is defintely hard for a competitor to replicate quickly, even with significant funding.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Focused Pipeline Amidst Tight Cash\u003c\/h3\u003e\n\u003cp\u003eSangamo Therapeutics is clearly organized around leveraging this technology, particularly in neurology with ST-503 progressing through its Phase 1\/2 STAND study. However, the organization's ability to fully exploit this advantage is constrained by its balance sheet. As of September 30, 2025, cash and cash equivalents stood at $29.6 million. This lean cash position means resource allocation is extremely tight, forcing a laser focus on the most promising near-term assets like ST-503 and ST-920 for Fabry disease, while actively pursuing business development to shore up the runway into 2026.\u003c\/p\u003e\n\u003cp\u003eThe company's structure is lean, but its financial footing demands external support to fully capitalize on its internal tech.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how the ZF technology scores:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eScore (1-4)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes, enables precise, durable regulation\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes, specialized and mature toolset\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly to replicate\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eFocused, but cash-constrained\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the immediate need to convert pipeline progress into non-dilutive funding.\u003c\/p\u003e\n\u003cp\u003eActionable Strategic Priorities Based on VRIO:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eMaximize ST-503 Value:\u003c\/strong\u003e Drive patient dosing in the Phase 1\/2 STAND study quickly.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAddress Organization Constraint:\u003c\/strong\u003e Aggressively pursue a commercialization partner for Fabry (ST-920) to secure non-dilutive cash.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProtect Imitability:\u003c\/strong\u003e Continue filing IP around novel ZF designs to maintain the high barrier to entry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSangamo Therapeutics, Inc. (SGMO) - VRIO Analysis: 2. STAC-BBB Proprietary Neurotropic AAV Capsid Platform\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvides a unique delivery vehicle capable of crossing the blood-brain barrier (BBB) with industry-leading Central Nervous System (CNS) tropism in nonhuman primates (NHPs). Preclinical data in NHPs demonstrated 700-fold higher transgene expression in neurons compared to the benchmark capsid AAV9 following intravenous administration. The capsid mediated robust transduction and targeted, potent epigenetic repression throughout the brain. The biodistribution profile showed enrichment in the CNS and de-targeting from the liver and dorsal root ganglia (DRG).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. Effective, non-invasive CNS delivery vectors are the holy grail in gene therapy. This platform is already licensed to three major partners. The company plans to pursue up to three neurology Investigational New Drug (IND) submissions and\/or Clinical Trial Applications (CTA) by the end of 2025, including an IND submission for a Chronic Neuropathic Pain program expected in the fourth quarter of 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. Capsid engineering is complex, requiring extensive screening and validation against biological barriers. The STAC-BBB variant was identified using Sangamo's SIFTER capsid platform, which leverages cell type specific measurement of capsid-mediated transgene expression, screening 1,260 capsids initially.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. The organization has successfully monetized this asset through license agreements, generating non-dilutive revenue. As of December 31, 2024, cash and cash equivalents were $41.9 million. Total revenues for 2024 were $57.8 million, compared to $176.2 million in 2023.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eUpfront Payment\u003c\/td\u003e\n\u003ctd\u003ePotential Milestones (Max)\u003c\/td\u003e\n\u003ctd\u003eTotal Potential Value (Approx.)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenentech\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to nearly \u003cstrong\u003e$2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUp to nearly \u003cstrong\u003e$2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstellas\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.32 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.32 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLilly\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTotal Upfront Cash\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$88 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Lilly agreement includes an upfront payment of $18 million and the option to include up to four additional targets beyond the initial one, for a total of up to five targets, with potential milestones up to $1.4 billion plus tiered royalties. The Astellas agreement grants a worldwide exclusive license for up to five potential neurological disease targets, with a $20 million upfront fee and up to $1.3 billion in milestones. The Genentech agreement, announced in August 2024, included a $50 million upfront payment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. The proven delivery capability, validated by three pharma deals, creates a significant moat. The total potential value from the three STAC-BBB license agreements is approximately $4.72 billion in milestones alone (using the higher Genentech estimate of $2 billion).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe platform enabled the company to secure $88 million in upfront, non-dilutive revenue from the three licensing deals.\u003c\/li\u003e\n\u003cli\u003eThe $18 million upfront payment from Lilly was critical, as the company had cash sufficient to fund operations only into the first quarter of 2025 as of November 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSangamo Therapeutics, Inc. (SGMO) - VRIO Analysis: 3. Clinical Data \u0026amp; Regulatory Pathway for Fabry Disease (ST-920)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOffers a potential one-time, durable treatment for Fabry disease, with sustained $\\alpha$-Gal A enzyme activity maintained for up to \u003cstrong\u003e4.5 years\u003c\/strong\u003e for the longest treated patient as of the latest data cutoff. \u003cstrong\u003eAll 18 patients\u003c\/strong\u003e who began the study on enzyme replacement therapy (ERT) have been withdrawn from, and remain off, ERT.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. Other Fabry therapies exist, including Fabrazyme by Sanofi (NASDAQ: SNY) Genzyme, the only FDA-approved ERT treatment in the U.S. at one point. The global Fabry Disease treatment market was expected to reach \u003cstrong\u003eUSD 3.12 billion by 2025\u003c\/strong\u003e, growing at a CAGR of \u003cstrong\u003e9.6%\u003c\/strong\u003e. A one-time gene therapy with this reported durability is rare.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow to Moderate. Competitors are in the space, but Sangamo has secured a clear FDA pathway.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. The team has successfully navigated the FDA to secure an Accelerated Approval pathway using the eGFR slope endpoint, potentially accelerating time to market by approximately \u003cstrong\u003ethree years\u003c\/strong\u003e. The FDA agreed that the eGFR slope at 52 weeks across all Phase 1\/2 patients can serve as the primary basis for approval.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. This advantage is tied to being first-to-file\/approve on this specific pathway; it erodes upon competitor entry or BLA approval. Potential Biologics License Application (BLA) submission is anticipated in the \u003cstrong\u003esecond half of 2025\u003c\/strong\u003e or as early as the \u003cstrong\u003efirst quarter of 2026\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eClinical Data Summary for ST-920 (Isaralgagene Civaparvovec) in Fabry Disease STAAR Study:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLongest $\\alpha$-Gal A Activity Maintenance\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.5 years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLongest treated patient follow-up.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients with $\\geq$ 1-Year Follow-up\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e23 patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eObserved positive mean eGFR slope.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMean Annualized eGFR Slope (52-Week)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3.061 mL\/min\/1.73m$2$\/year\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrimary efficacy endpoint for Accelerated Approval (95% CI: 0.863, 5.258).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patients Dosed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33 patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCompleted enrollment in Phase 1\/2 STAAR study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients Withdrawn from ERT\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18 patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAll patients who started on ERT are now off ERT.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eRegulatory Milestones and Timelines:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFDA agreement on Accelerated Approval pathway using eGFR slope at 52 weeks as intermediate clinical endpoint.\u003c\/li\u003e\n\u003cli\u003eData to support Accelerated Approval pathway expected in the \u003cstrong\u003efirst half of 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePotential BLA submission anticipated in the \u003cstrong\u003esecond half of 2025\u003c\/strong\u003e or as early as the \u003cstrong\u003efirst quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFDA granted Orphan Drug, Fast Track, and RMAT designations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSangamo Therapeutics, Inc. (SGMO) - VRIO Analysis: 4. Strategic Partnerships \u0026amp; Non-Dilutive Funding Stream\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e De-risks the balance sheet and validates the core technology through upfront payments and milestone potential, such as the up to \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e potential from the Lilly deal. The Lilly upfront payment was \u003cstrong\u003e$18 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs have partnerships, but Sangamo’s focus on licensing its platform (capsids) alongside its pipeline assets is a distinct strategy, evidenced by securing three STAC-BBB agreements since March 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. Big pharma seeks out validated tech, but the specific terms and targets are unique to Sangamo’s current pipeline focus.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company has demonstrated an ability to close deals, securing license fees that helped extend its cash runway into early \u003cstrong\u003e2026\u003c\/strong\u003e or late Q3 \u003cstrong\u003e2025\u003c\/strong\u003e. The \u003cstrong\u003e$18.0 million\u003c\/strong\u003e upfront license fee from Lilly contributed to funding planned operations.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. This is a transactional advantage; it relies on continuous deal execution, which can be cyclical.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKey Partnership Financial Metrics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eAsset\/Platform\u003c\/td\u003e\n\u003ctd\u003eUpfront\/Near-Term Payment\u003c\/td\u003e\n\u003ctd\u003eTotal Potential Value (Excl. Royalties)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEli Lilly and Company\u003c\/td\u003e\n\u003ctd\u003eSTAC-BBB Capsid (CNS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenentech (Roche Group)\u003c\/td\u003e\n\u003ctd\u003eEpigenetic Regulation \u0026amp; Capsid Delivery\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$50.0 million\u003c\/strong\u003e (expected near-term)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.9 billion\u003c\/strong\u003e (milestones)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstellas\u003c\/td\u003e\n\u003ctd\u003eCapsid License (Neurological)\u003c\/td\u003e\n\u003ctd\u003eNot specified\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.32 billion\u003c\/strong\u003e (pact value)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer\u003c\/td\u003e\n\u003ctd\u003eGiroctocogene Fitelparvovec (Hemophilia A)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Deal terminated)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$220.0 million\u003c\/strong\u003e (milestones)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eNon-Dilutive Funding Stream Highlights:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Genentech agreement, along with near-term payments, extended the cash runway into early \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of December 31, 2024, were \u003cstrong\u003e$41.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company is actively seeking a commercialization partner for its Fabry program to extend its cash runway until key data readouts in Q4 \u003cstrong\u003e2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIn November 2025, Sangamo received \u003cstrong\u003e$6 million\u003c\/strong\u003e from Pfizer following the exercise of a buyout option on certain cell line licenses.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSangamo Therapeutics, Inc. (SGMO) - VRIO Analysis: 5. Pipeline Depth in Neurology (Pain\/Prion)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Diversifies risk away from the lead Fabry program and targets large (neuropathic pain) or high-unmet-need (prion disease) markets.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eKey Technology\u003c\/th\u003e\n\u003cth\u003eExpected Milestone\u003c\/th\u003e\n\u003cth\u003eMarket Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eST-503\u003c\/td\u003e\n\u003ctd\u003eChronic Neuropathic Pain (iSFN)\u003c\/td\u003e\n\u003ctd\u003eEpigenetic Regulator (ZFR)\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2 Dosing Start: \u003cstrong\u003eMid-2025\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eGlobal Neuropathic Pain Market (2025 Est.): \u003cstrong\u003e$9,462.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eST-506\u003c\/td\u003e\n\u003ctd\u003ePrion Disease\u003c\/td\u003e\n\u003ctd\u003eEpigenetic Regulator (ZFR) + STAC-BBB\u003c\/td\u003e\n\u003ctd\u003eCTA Submission Expected: \u003cstrong\u003eQ1 2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHigh Unmet Need (No approved disease-modifying therapies)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe STAC-BBB capsid platform is leveraged in the Prion program and has a separate license agreement with Lilly for up to \u003cstrong\u003e5\u003c\/strong\u003e CNS targets, including an \u003cstrong\u003e$18.0 million\u003c\/strong\u003e upfront payment and up to \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e in milestones.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs focus on one rare disease; Sangamo is actively advancing three distinct neurology programs (Fabry, Pain, Prion).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate. The scientific foundation (ZF\/Capsid) is rare, but the specific disease targets require unique development pathways.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. They are executing on multiple fronts, with ST-503 dosing underway and CTA-enabling work for ST-506 progressing well.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eST-503 (Pain) received \u003cstrong\u003eFast Track Designation\u003c\/strong\u003e from the FDA.\u003c\/li\u003e\n\u003cli\u003ePreliminary proof of efficacy data anticipated for ST-503 in \u003cstrong\u003eQ4 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePreliminary clinical data anticipated for ST-506 (Prion) in \u003cstrong\u003eQ4 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of \u003cstrong\u003e$29.616 million\u003c\/strong\u003e (09\/30\/2025).\u003c\/li\u003e\n\u003cli\u003eCash and cash equivalents as of \u003cstrong\u003e$25.2 million\u003c\/strong\u003e (03\/31\/2025).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. A deep, focused pipeline built on a common platform offers long-term optionality.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSangamo Therapeutics, Inc. (SGMO) - VRIO Analysis: 6. Expertise in Gene Therapy Manufacturing and CMC\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Essential for commercial viability; a clear Chemistry, Manufacturing, and Controls (CMC) pathway is needed for any regulatory submission. The successful navigation of the CMC requirements for isaralgagene civaparvovec (ST-920) directly supports the potential for an Accelerated Approval pathway for Fabry disease.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. While many biotechs have manufacturing partners, Sangamo has achieved alignment with the FDA on a clear CMC pathway for its Biologics License Application (BLA) submission for ST-920. This alignment was confirmed following a productive Type B CMC meeting in April 2025. The FDA has accepted Sangamo's request for a rolling submission and review of the BLA for ST-920.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Mastering the scale-up and quality control for a one-time gene therapy product is a major hurdle for new entrants. The company's progress indicates established internal or closely managed external capabilities to meet commercial specifications.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Productive Type B CMC meetings with the FDA show the organization is prepared for the technical requirements of commercialization. The organization is advancing BLA readiness activities, with a planned rolling BLA submission to the FDA under the accelerated approval pathway later in the fourth quarter of 2025. GAAP operating expenses for the third quarter ended September 30, 2025, were $36.1 million, which included increased clinical and manufacturing expenses related to BLA readiness for the Fabry disease program.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Manufacturing expertise in novel modalities is a long-term barrier to entry. The successful navigation of the regulatory path for ST-920, which has seen 32 dosed patients in the STAAR study, validates the underlying CMC processes.\u003c\/p\u003e\n\n\u003cp\u003eKey Regulatory and CMC Milestones for ST-920:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\/Event\u003c\/th\u003e\n\u003cth\u003eDetail\/Value\u003c\/th\u003e\n\u003cth\u003eDate\/Status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Agreement on Endpoint\u003c\/td\u003e\n\u003ctd\u003eeGFR slope at 52-weeks as primary basis for approval\u003c\/td\u003e\n\u003ctd\u003eReiterated October 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eType B CMC Meeting with FDA\u003c\/td\u003e\n\u003ctd\u003eProvided clear CMC pathway to planned BLA submission\u003c\/td\u003e\n\u003ctd\u003eApril 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDosing Completion (STAAR Study)\u003c\/td\u003e\n\u003ctd\u003eTotal patients dosed\u003c\/td\u003e\n\u003ctd\u003e32 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlanned BLA Submission Timeline\u003c\/td\u003e\n\u003ctd\u003eInitiate rolling submission\u003c\/td\u003e\n\u003ctd\u003eFourth Quarter of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eeGFR Slope at 52-Weeks\u003c\/td\u003e\n\u003ctd\u003eMean annualized slope across all dosed patients\u003c\/td\u003e\n\u003ctd\u003ePositive (Data Cutoff September 12, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eeGFR Slope at 104-Weeks (19 Patients)\u003c\/td\u003e\n\u003ctd\u003eMean annualized slope\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.747 mL\/min\/1.73m\u003csup\u003e2\u003c\/sup\u003e\/year\u003c\/strong\u003e (95% CI: -0.106, 3.601)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe company's organizational readiness is further evidenced by the regulatory designations granted to ST-920, which streamline development and review, indirectly validating the CMC package quality:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOrphan Drug designation from the FDA.\u003c\/li\u003e\n\u003cli\u003eFast Track and RMAT designations from the FDA.\u003c\/li\u003e\n\u003cli\u003ePRIME eligibility from the European Medicines Agency (EMA).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSangamo Therapeutics, Inc. (SGMO) - VRIO Analysis: 7. Intellectual Property (IP) Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Creates a legal barrier protecting the core ZF designs, specific capsid sequences (like STAC-BBB), and therapeutic applications. Historical upfront payments include $3.0 million from Pfizer (2009\/2010) and $20.0 million (including a $4.9 million equity component) from Sigma-Aldrich for ZFP technology licenses. A recent $6 million payment was received from Pfizer in October 2025 related to a buyout option on a 2008 license.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. All biotechs have IP, but Sangamo’s IP covers the foundational technology and its application in CNS delivery. As of February 2020, core ZFP\/ZFN\/ZFP-TF licenses encompassed four U.S. and over 20 foreign active granted patents.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Patents provide legal protection against direct copying of their engineered components. Specific granted patents include those related to AAV capsids (e.g., Patent No. 11981967, granted May 14, 2024) and C9orf72 modulation (e.g., Patent No. 12139517, granted November 12, 2024).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. The IP is the foundation, but its value is only realized through successful clinical execution and enforcement. Total operating expenses in Q3 2025 were $36.1 million GAAP, which included lower licensing and patent-related expenses compared to Q3 2024 ($\\mathbf{\\$38.8}$ million GAAP).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Patents offer the longest-lasting protection, provided they are broad and well-defended. The portfolio is continuously being strengthened with new filings, such as a Base Editor system application filed on December 22, 2022, with a projected publication date of November 27, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Asset\/Agreement Type\u003c\/th\u003e\n\u003cth\u003eQuantitative Metric\u003c\/th\u003e\n\u003cth\u003eAssociated Value\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSigma-Aldrich Upfront Payment\u003c\/td\u003e\n\u003ctd\u003eTotal Upfront Payment\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer ZFN License (2009\/2010)\u003c\/td\u003e\n\u003ctd\u003eUpfront Fee\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer Buyout Option Exercise (2025)\u003c\/td\u003e\n\u003ctd\u003eCash Received\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZFP\/ZFN\/ZFP-TF Patents (Feb 2020)\u003c\/td\u003e\n\u003ctd\u003eActive Granted Patents (US + Foreign)\u003c\/td\u003e\n\u003ctd\u003eFour U.S. and over \u003cstrong\u003e20\u003c\/strong\u003e Foreign\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUC\/CMCC Licensed Patent Families (Feb 2020)\u003c\/td\u003e\n\u003ctd\u003ePending US Patent Applications\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eThree\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eScope of Patent Portfolio (as of early 2020 filings):\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFor two core ZFP patent families, there were four U.S. and over 20 foreign active granted patents.\u003c\/li\u003e\n\u003cli\u003eFor licenses with UC and CMCC related to CNS disorders and hemoglobinopathies, the portfolio included three issued U.S. patents, 12 allowed or granted foreign patents, 25 pending foreign patent applications, and three pending U.S. patent applications.\u003c\/li\u003e\n\u003cli\u003eRecent granted patents include Patent No. 12043650 (CFTR gene modification), granted July 23, 2024.\u003c\/li\u003e\n\u003cli\u003eRecent granted patents include Patent No. 12139517 (C9orf72 modulation), granted November 12, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSangamo Therapeutics, Inc. (SGMO) - VRIO Analysis: 8. Organizational Focus and Pivot to Neurology\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Concentrating limited resources on a high-potential therapeutic area (neurology) where their core tech (ZF regulators and CNS capsids) is best suited.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIND application submitted to FDA for ST-503 for intractable pain due to idiopathic small fiber neuropathy (iSFN).\u003c\/li\u003e\n\u003cli\u003eCTA submission for prion disease program is expected in the fourth quarter of 2025.\u003c\/li\u003e\n\u003cli\u003ePatient dosing for ST-503 expected to commence in mid-2025.\u003c\/li\u003e\n\u003cli\u003eThe company is leveraging its zinc finger technology and AAV delivery platform, including the STAC-BBB capsid, to target neurological diseases.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many older biotechs struggle to pivot; Sangamo has successfully re-aligned its pipeline focus.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe strategic transformation involved a restructuring and US workforce reduction of approximately \u003cstrong\u003e40%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCost savings from restructuring and other reductions were anticipated to reduce annual operating expenses by approximately \u003cstrong\u003e50%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company is deferring additional investments in its Fabry gene therapy and CAR-Treg cell therapy programs until funding is secured.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Strategy is imitable, but the execution of a successful pivot requires specific leadership and scientific alignment.\u003c\/p\u003e\n\u003cp\u003eExecution is evidenced by securing multiple high-value, neurology-focused collaborations leveraging their proprietary technology:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner\u003c\/td\u003e\n\u003ctd\u003eTechnology Focus\u003c\/td\u003e\n\u003ctd\u003eUpfront\/Near-Term Payment\u003c\/td\u003e\n\u003ctd\u003eTotal Potential Milestones\/Fees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenentech\u003c\/td\u003e\n\u003ctd\u003eEpigenetic Regulation \u0026amp; Capsid Delivery (Neurodegenerative)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.9 billion\u003c\/strong\u003e + tiered royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAstellas\u003c\/td\u003e\n\u003ctd\u003eCapsid Delivery (Up to 5 Neurological Targets)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.3 billion\u003c\/strong\u003e + tiered royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEli Lilly and Company (Lilly)\u003c\/td\u003e\n\u003ctd\u003eCapsid Delivery (Up to 5 CNS Targets using STAC-BBB)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e + tiered royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Leadership has clearly communicated and executed this strategic shift, evidenced by the new neurology-focused deals and pipeline advancement.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal revenue for Q3 2024 was \u003cstrong\u003e$49.4 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$9.4 million\u003c\/strong\u003e for the same period in 2023, with the increase attributed primarily to the Genentech collaboration.\u003c\/li\u003e\n\u003cli\u003eReported Q3 2024 EPS of \u003cstrong\u003e$0.04\u003c\/strong\u003e, significantly beating the analyst estimate of \u003cstrong\u003e-$0.03\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSecured over \u003cstrong\u003e$100 million\u003c\/strong\u003e in funding in 2024 through non-dilutive license fees and milestone payments, alongside equity financing.\u003c\/li\u003e\n\u003cli\u003eFull-year 2024 non-GAAP total operating expense guidance was in the range of approximately \u003cstrong\u003e$125 million to $145 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Strategic focus can shift quickly if early neurology trials fail to meet expectations.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents were \u003cstrong\u003e$27.8 million\u003c\/strong\u003e as of June 30, 2024.\u003c\/li\u003e\n\u003cli\u003eThe company is advancing its wholly-owned neurology pipeline while continuing to seek a collaboration partner for its Hemophilia A program following Phase 3 results.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSangamo Therapeutics, Inc. (SGMO) - VRIO Analysis: 9. Preclinical Proof-of-Concept in Complex Diseases (e.g., Prion)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eDemonstrates the platform’s potential to address previously 'undruggable' or highly complex targets, like reducing prion mRNA in the brain, evidenced by survival extension in mouse models. The $\\text{hSYN1-ZF-R}$ treatment significantly extends survival compared to vehicle groups, which reached terminal endpoint at $\\mathbf{160\\pm8}$ days post-inoculation ($\\text{dpi}$).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. Showing profound survival extension in mouse models for a prion disease is a significant scientific achievement. A majority of $\\text{AAV-ZF-R}$ treated mice ($\\text{n}=10\/19$) were alive $\\mathbf{1}$ year after inoculation, and $\\mathbf{5\/19}$ mice survived to the scheduled necropsy date of $\\mathbf{500}$ dpi.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. Requires deep, specialized scientific expertise to design and execute such complex preclinical studies, including the use of $\\text{AAV.PHP.B}$ for blood-brain-barrier ($\\text{BBB}$) penetration and $\\text{ZF-Rs}$ utilizing a human $\\text{KRAB}$ transcriptional repression domain.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate. The organization has the scientific bench strength to generate this data, with Research \u0026amp; Development expenses reported at $\\mathbf{\\$221.66}$ million for the year ended December 31, 2023. A $\\text{CTA}$ submission for the prion program is expected in the fourth quarter of $\\mathbf{2025}$.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. Early, compelling data in a novel, difficult area can attract future partnerships and talent, as evidenced by raising over $\\mathbf{\\$100}$ million in funding in $\\mathbf{2024}$ and securing a capsid license agreement with Astellas in December $\\mathbf{2024}$ potentially worth up to $\\mathbf{\\$1.3}$ billion in future payments.\u003c\/p\u003e\n\u003cp\u003eKey Preclinical Proof-of-Concept Metrics for Prion Disease Program:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eResult\/Finding\u003c\/td\u003e\n\u003ctd\u003eContext\/Model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurvival Extension\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{5\/19}$ mice survived to $\\mathbf{500}$ dpi\u003c\/td\u003e\n\u003ctd\u003eRML mouse model treated post-symptomatically\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurvival Rate at 1 Year\u003c\/td\u003e\n\u003ctd\u003eMajority ($\\mathbf{10\/19}$) alive at $\\mathbf{1}$ year post-inoculation\u003c\/td\u003e\n\u003ctd\u003eRML mouse model\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVehicle Endpoint\u003c\/td\u003e\n\u003ctd\u003e$\\mathbf{160\\pm8}$ dpi (mean$\\pm$sd)\u003c\/td\u003e\n\u003ctd\u003eAAV GFP and vehicle groups\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGene Repression Mechanism\u003c\/td\u003e\n\u003ctd\u003e$\\text{ZF-Rs}$ utilize a human $\\text{KRAB}$ transcriptional repression domain\u003c\/td\u003e\n\u003ctd\u003eMechanism of action\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery Vector\u003c\/td\u003e\n\u003ctd\u003e$\\text{AAV.PHP.B}$ used for $\\text{BBB}$ penetration\u003c\/td\u003e\n\u003ctd\u003ePreclinical study component\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003ePipeline Advancement Milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e$\\text{CTA}$ submission expected in the fourth quarter of $\\mathbf{2025}$.\u003c\/li\u003e\n\u003cli\u003eConsolidated net loss for the year ended December 31, 2024, was $\\mathbf{\\$97.9}$ million.\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents as of December 31, 2024, were $\\mathbf{\\$41.9}$ million.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516249464981,"sku":"sgmo-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sgmo-vrio-analysis.png?v=1740212981","url":"https:\/\/dcf-model.com\/pt\/products\/sgmo-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}